Cargando…
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study
OBJECTIVE: To assess the efficacy and safety of enzyme replacement therapy (ERT) with BMN 110 (elosulfase alfa) in patients with Morquio A syndrome (mucopolysaccharidosis IVA). METHODS: Patients with Morquio A aged ≥5 years (N = 176) were randomised (1:1:1) to receive elosulfase alfa 2.0 mg/kg/every...
Autores principales: | Hendriksz, Christian J., Burton, Barbara, Fleming, Thomas R., Harmatz, Paul, Hughes, Derralynn, Jones, Simon A., Lin, Shuan-Pei, Mengel, Eugen, Scarpa, Maurizio, Valayannopoulos, Vassili, Giugliani, Roberto, Slasor, Peter, Lounsbury, Debra, Dummer, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206772/ https://www.ncbi.nlm.nih.gov/pubmed/24810369 http://dx.doi.org/10.1007/s10545-014-9715-6 |
Ejemplares similares
-
Role of elosulfase alfa in mucopolysaccharidosis IVA
por: Regier, Debra S, et al.
Publicado: (2016) -
Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y
por: Jones, Simon A., et al.
Publicado: (2015) -
Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome
por: Hendriksz, Christian J., et al.
Publicado: (2016) -
Elosulfase alfa for mucopolysaccharidosis type IVA: Real-world experience in 7 patients from the Spanish Morquio-A early access program
por: Pintos-Morell, Guillem, et al.
Publicado: (2018) -
Efficacy of Intravenous Elosulfase Alfa for Mucopolysaccharidosis Type IVA: A Systematic Review and Meta-Analysis
por: Lee, Chung-Lin, et al.
Publicado: (2022)